| Gary D Walters, NP | |
|
1830 Flower St, Bakersfield, CA 93305-4144 | |
| (661) 872-3311 | |
| (661) 872-3366 |
| Full Name | Gary D Walters |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Location | 1830 Flower St, Bakersfield, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528259207 | NPI | - | NPPES |
| 11913 | Other | CA | NP LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 11913 (California) | Secondary |
| 363L00000X | Nurse Practitioner | 11913 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Gary D Walters, NP 1830 Flower St, Bakersfield, CA 93305-4144 Ph: (661) 872-3311 | Gary D Walters, NP 1830 Flower St, Bakersfield, CA 93305-4144 Ph: (661) 872-3311 |
News Archive
Three-year data from the prospective, randomized LEADERS trial demonstrate the equivalence of a biolimus A9-eluting stent with a biodegradable polymer vs. a sirolimus-eluting stent with a durable polymer. The results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.
Although estimates vary widely, when combined with the milder afflictions of Alcohol Related Birth Defects (ARBD) and several others, the Centers for Disease Control puts the frequency of FAS/ARBD as high as one in 100.
As the month of November kicks off PH Awareness Month, Dr. Ronald Oudiz - lead investigator at the Los Angeles Biomedical Research Institute (LA BioMed) - hopes to bring greater awareness to this disorder that has affected the lives of so many. Dr. Oudiz is a pioneer in this field, having received the 2011 Award for Excellence earlier this year from the Pulmonary Hypertension Association for his dedication to find new ways to treat this often fatal disease.
Researchers at the Ecole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique- already in practice in Europe - for the American market. Under the name Cysview-, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.
A drug that appears to target specific intestinal bacteria in the guts of mice may create a chain reaction that could eventually lead to new treatments for obesity and diabetes in humans, according to a team of researchers.
› Verified 4 days ago